Evidence map›Paper›PMID 33263761›Full record

ArticleJAMA network open2020

Trajectory of Unawareness of Memory Decline in Individuals With Autosomal Dominant Alzheimer Disease.

Patrizia Vannini, Bernard J Hanseeuw, Jennifer R Gatchel, Sietske A M Sikkes, Diana Alzate, Yesica Zuluaga, Sonia Moreno, Luis Mendez, Ana Baena, Paula Ospina-Lopera and 6 more

Open access · goldAbstract read
In one paragraph

Article in JAMA network open, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed, 1 pooled it
4.1field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 1 synthesis or guideline pooled it, 44 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Review
  8. Subjective cognitive decline: Memory complaints, cognitive awareness, and metacognition.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2024
    Review
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Review
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 6 institutions in 4 countries.

Patrizia VanniniDepartment of Radiology, Athinoula A. Martinos Center for Biomedical Imaging, Charlestown, Massachusetts.
Bernard J HanseeuwDepartment of Radiology, Athinoula A. Martinos Center for Biomedical Imaging, Charlestown, Massachusetts.
Jennifer R GatchelHarvard Medical School, Boston, Massachusetts.
Sietske A M SikkesAmsterdam University Medical Centers, Alzheimer Center Amsterdam, Amsterdam, the Netherlands.
Diana AlzateGrupo de Neurociencias de Antioquia, School of Medicine, Universidad de Antioquia, Medellin, Colombia.
Yesica ZuluagaGrupo de Neurociencias de Antioquia, School of Medicine, Universidad de Antioquia, Medellin, Colombia.
Sonia MorenoGrupo de Neurociencias de Antioquia, School of Medicine, Universidad de Antioquia, Medellin, Colombia.
Luis MendezGrupo de Neurociencias de Antioquia, School of Medicine, Universidad de Antioquia, Medellin, Colombia.
Ana BaenaDepartment of Psychiatry, Massachusetts General Hospital, Boston.
Paula Ospina-LoperaGrupo de Neurociencias de Antioquia, School of Medicine, Universidad de Antioquia, Medellin, Colombia.
Victoria TiradoGrupo de Neurociencias de Antioquia, School of Medicine, Universidad de Antioquia, Medellin, Colombia.
Eliana HenaoGrupo de Neurociencias de Antioquia, School of Medicine, Universidad de Antioquia, Medellin, Colombia.
Natalia Acosta-BaenaGrupo de Neurociencias de Antioquia, School of Medicine, Universidad de Antioquia, Medellin, Colombia.
Margarita GiraldoGrupo de Neurociencias de Antioquia, School of Medicine, Universidad de Antioquia, Medellin, Colombia.
Francisco LoperaGrupo de Neurociencias de Antioquia, School of Medicine, Universidad de Antioquia, Medellin, Colombia.
Yakeel T QuirozDepartment of Radiology, Athinoula A. Martinos Center for Biomedical Imaging, Charlestown, Massachusetts.
Universidad de Antioquia · COAmsterdam University Medical Centers · NLAthinoula A. Martinos Center for Biomedical Imaging · USHarvard University · USMassachusetts General Hospital · USUCLouvain · BE

Funding

Decoding neural systems underlying anosognosia for memory loss in aging and Alzheimer's diseaseR01AG061083 · NIA · BRIGHAM AND WOMEN'S HOSPITAL · PI VANNINI, PATRIZIA · 2019 to 2023
$4.3M
Depressive symptoms in the pathogenesis of preclinical Alzheimer's DiseaseK23AG058805 · NIA · MASSACHUSETTS GENERAL HOSPITAL · PI GATCHEL, JENNIFER ROSE · 2018 to 2022
$992k
NIA NIH HHS K23 AG058805NIA NIH HHS R01 AG061083
6 · The paper itself

Abstract

Importance: Recent studies have suggested that unawareness, or anosognosia, of memory decline is present in predementia stages of Alzheimer disease (AD) and may serve as an early symptomatic indicator of AD. Objective: To investigate the evolution of anosognosia of memory decline in individuals who carry the PSEN1 E280A variant for autosomal dominant AD compared with family members who do not carry the variant. Design, Setting, and Participants: This cohort study investigated a total of 2379 members of a Colombian kindred with autosomal dominant AD who were part of the Alzheimer's Prevention Initiative Registry. Assessments were completed at the University of Antioquia, Colombia, with data collected between January 1, 2000, and July 31, 2019. Main Outcomes and Measures: Awareness of memory function was operationalized using the discrepancy between self-report and study partner report on a memory complaint scale. Linear mixed effects models were used to assess memory self-awareness over age separately in variant carriers and noncarriers. Results: This study included 396 variant carriers (mean [SD] age, 32.7 [11.9] years; 200 [50.5%] female), of whom 59 (14.9%) were cognitively impaired, and 1983 cognitively unimpaired noncarriers (mean [SD] age, 33.5 [12.5] years; 1129 [56.9%] female). The variant carriers demonstrated increased awareness until the mean (SD) age of 35.0 (2.0) years and had anosognosia at approximately 43 years of age, approximately 6 years before their estimated median age of dementia onset (49 years; 95% CI, 49-51 years). Cognitively unimpaired noncarriers reported more complaints than their study partners aged 20 and 60 years (10.1 points, P < .001). On the awareness index, a decrease with age (mean [SE] estimate, -0.04 [0.02] discrepant-points per years; t = -2.2; P = .03) in the noncarriers and in the variant carriers (mean [SE] estimate, -0.21 [0.04] discrepant-points per years; t = -5.1; P < .001) was observed. Conclusions and Relevance: In this cohort study, increased participant complaints were observed in both groups, suggesting that increased awareness of memory function was common and nonspecific to AD in this cohort. In variant carriers, awareness of memory function decreased in the predementia stages, reaching anosognosia close to the age of mild cognitive impairment onset, providing support for the usefulness of awareness of memory decline.

Indexed as

AdultAgnosiaAlzheimer DiseaseCognitive DysfunctionColombiaFemaleGenetic VariationHeterozygoteHumansLongitudinal StudiesMaleMemory DisordersMiddle AgedPresenilin-1RegistriesRisk FactorsPresenilin-1PSEN1 protein, human

Identifiers

PMID33263761
PMCPMC7711319
OpenAlexW3108007701

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.